Abstract：
UNASSIGNED: Drug-induced interstitial lung disease (DI-ILD) is increasing in incidence, due to the use of many new drugs across a broad range of cancers and chronic inflammatory diseases. The presentation and onset of DI-ILD are variable even for the same drug across different individuals. Clinical suspicion is essential for identifying these conditions, with timely drug cessation an important determinant of outcomes.
UNASSIGNED: This review provides a comprehensive and up-to-date summary of epidemiology, risk factors, pathogenesis, diagnosis, treatment, and prognosis of DI-ILD. Relevant research articles from PubMed and Medline searches up to September 2023 were screened and summarized. Specific drugs including immune checkpoint inhibitors, CAR-T cell therapy, methotrexate, and amiodarone are discussed in detail. The potential role of pharmacogenomic profiling for lung toxicity risk is considered.
UNASSIGNED: DI-ILD is likely to be an increasingly important contributor to respiratory disability in the community. These conditions can negatively impact quality of life and patient longevity, due to associated respiratory compromise as well as cessation of evidence-based therapy for the underlying disease. This clinical conundrum is relevant to all areas of medicine, necessitating increased understanding and greater vigilance for drug-related lung toxicity.
UNASSIGNED: This review provides a comprehensive and up-to-date summary of epidemiology, risk factors, pathogenesis, diagnosis, treatment, and prognosis of DI-ILD. Relevant research articles from PubMed and Medline searches up to September 2023 were screened and summarized. Specific drugs including immune checkpoint inhibitors, CAR-T cell therapy, methotrexate, and amiodarone are discussed in detail. The potential role of pharmacogenomic profiling for lung toxicity risk is considered.
UNASSIGNED: DI-ILD is likely to be an increasingly important contributor to respiratory disability in the community. These conditions can negatively impact quality of life and patient longevity, due to associated respiratory compromise as well as cessation of evidence-based therapy for the underlying disease. This clinical conundrum is relevant to all areas of medicine, necessitating increased understanding and greater vigilance for drug-related lung toxicity.
摘要：
■药物诱发的间质性肺病（DI-ILD）的发病率正在增加，由于在广泛的癌症和慢性炎症性疾病中使用了许多新药。即使对于不同个体的相同药物,DI-ILD的呈现和发作也是可变的。临床怀疑对于识别这些疾病至关重要，及时停药是结局的重要决定因素。
■这篇综述提供了全面和最新的流行病学摘要，危险因素，发病机制，诊断,治疗,和DI-ILD的预后。截至2023年9月，PubMed和Medline搜索的相关研究文章进行了筛选和总结。特异性药物包括免疫检查点抑制剂，CAR-T细胞疗法,甲氨蝶呤,和胺碘酮进行了详细讨论。考虑了药物基因组学分析对肺毒性风险的潜在作用。
■DI-ILD可能是社区中呼吸功能障碍的一个越来越重要的因素。这些情况会对生活质量和患者寿命产生负面影响，由于相关的呼吸损害以及对基础疾病的循证治疗的停止。这个临床难题与医学的所有领域有关，需要增加对药物相关肺毒性的了解和更高的警惕。
■这篇综述提供了全面和最新的流行病学摘要，危险因素，发病机制，诊断,治疗,和DI-ILD的预后。截至2023年9月，PubMed和Medline搜索的相关研究文章进行了筛选和总结。特异性药物包括免疫检查点抑制剂，CAR-T细胞疗法,甲氨蝶呤,和胺碘酮进行了详细讨论。考虑了药物基因组学分析对肺毒性风险的潜在作用。
■DI-ILD可能是社区中呼吸功能障碍的一个越来越重要的因素。这些情况会对生活质量和患者寿命产生负面影响，由于相关的呼吸损害以及对基础疾病的循证治疗的停止。这个临床难题与医学的所有领域有关，需要增加对药物相关肺毒性的了解和更高的警惕。
